Anti-CD22 Neutralizing Antibody (V3S-0622-YC4309) (CAT#: V3S-0622-YC4309)

Figure 1 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in SDS-PAGE

SDS-PAGE analysis of V3S-0622-YC4309 in non-reduced and β-mercaptoethanol-reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as about 180 kDa.

Figure 2 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in SEC-HPLC

The purity of V3S-0622-YC4309 was greater than 99% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.3
Detection: UV 280 nm
Injection: 25 µl

Figure 3 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in ELISA

ELISA analysis of V3S-0622-YC4309 was performed by coating with Recombinant Human CD22 Protein. Then blocked with BSA, and incubated with Anti-Human CD22 Antibody (V3S-0622-YC4309). The HRP-conjugated anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 4 Anti-CD22 Monoclonal Antibody (V3S-0622-YC4309) in WB

Western blot analysis of V3S-0622-YC4309 was performed by loading Recombinant Human CD22 Protein onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC4309 and HRP Anti-Human IgG as a secondary antibody. Chemiluminescent detection was performed.
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)